Glutamate and psychiatric disorders

Advances in Psychiatric Treatment

Volumn 8, Issue 3, 2002, Pages 189-197

  Tsapakis, Eva M ^a   Travis, Michael J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; AMPA RECEPTOR; AMPHETAMINE DERIVATIVE; CYCLOSERINE; DEXTRO SERINE; DIZOCILPINE; DOPAMINE; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLYCINE; GLYCINE DERIVATIVE; HALOPERIDOL; ION CHANNEL; IONOTROPIC RECEPTOR; KAINIC ACID RECEPTOR; KETAMINE; LAMOTRIGINE; LORAZEPAM; LYSERGIDE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; PHENCYCLIDINE; PSYCHEDELIC AGENT; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; UNINDEXED DRUG;

ANXIETY NEUROSIS; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; DELUSION; DEPRESSION; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HALLUCINATION; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PSYCHOSIS; SCHIZOPHRENIA; THOUGHT DISORDER;

EID: 0036267049     PISSN: 13555146     EISSN: None     Source Type: Journal    
DOI: 10.1192/apt.8.3.189     Document Type: Article

References (41)

1. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms
2. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine
3. Symptoms of schizophrenia. Methods, meanings, and mechanisms
4. The dissociative anesthetics ketamine and phencyclidine selectively reduce excitation of central mammalian neurons by N-methyl-D-aspartate
5. Antidepressant effects of ketamine in depressed patients
6. Chronic administration of imipramine and citalopram alters the expression of NMDA receptor subunit mRNAs in mouse brain. A quantitative in situ hybridisation study
7. Imaging the glutamatergic system in vivo - Relevance to schizophrenia
8. A double-blind placebo-controlled study of lamotrigine monotherapy in out-patients with bipolar I depression
9. Neurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
10. A glutamatergic deficiency model of schizophrenia
11. Interactions between monoamines, glutamate, and GABA in schizophrenia: New evidence
12. Neurotransmission in the rat amygdala related to fear and anxiety
13. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity
14. Glutamate in schizophrenia: Clinical and research implications
15. A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia
16. Safety and tolerability of the glutamate antagonist CGS 19755 (Selfotel) in patients with acute ischaemic stroke. Results of a phase IIa randomised trial
17. Evidence for biochemical heterogeneity in schizophrenia: A multivariate study of monoaminergic indices in human post-mortem brain tissue
18. Efficacy of high-dose glycine in the treatment of enduring negative symptoms
19. Recent advances in the phencyclidine model of schizophrenia
20. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: Implications for schizophrenia
21. Subanaesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses
22. Pharmacologic model of psychoses
23. Interactive effects of subanaesthetic ketamine and haloperidol
24. Current perspectives on the pathophysiology of schizophrenia, depression, and anxiety disorders
25. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects
26. Intracellular modulation of NMDA receptor function by anti-psychotic drugs
27. 2A and group II metabotropic glutamate receptors in prefrontal cortex
28. 2A receptor antagonism is dependent on increased serotonergic tone
29. Glutamate receptor expression in schizophrenic brain
30. Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex
31. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats
32. Fear-potentiated startle in post-traumatic stress disorder
33. Ketamine-induced NMDA receptor hypofunction as model of memory impairment and psychosis
34. Excitotoxic neurodegeneration in Alzheimer's disease: New hypothesis and new therapeutic strategies
35. Adaptation of N-methyl-D-aspartate receptor complex following chronic antidepressant treatments
36. 123I-IBZM SPET study
37. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
38. Schizophrenia and glutamate
39. Limbic system abnormalities identified in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with deficit syndrome
40. Antiglutamatergic therapy in Alzheimer's disease: Effects of lamotrigine
41. D-serine added to antipsychotics for the treatment of schizophrenia